SCHEMBL17899154

SCHEMBL17899154

CC(=O)c1ccc(C(N)=O)cc1Nc1ccc(C2CCN(C(C)C)CC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 6/20 0.42
EGFR P00533 1/20 0.41
LCK P06239 1/20 0.41
JAK3 P52333 1/20 0.41
BTK Q06187 1/20 0.41
ESRRG P62508 4/20 0.39
KCNH2 Q12809 2/20 0.39
ESRRB O95718 2/20 0.39
ESR1 P03372 1/20 0.39
KDM1A O60341 2/20 0.39
MAOA P21397 2/20 0.39
KDM1B Q8NB78 2/20 0.39
RCOR1 Q9UKL0 2/20 0.39
HRH3 Q9Y5N1 1/20 0.39
SYK P43405 2/20 0.39
PARP2 Q9UGN5 2/20 0.37
PTK2 Q05397 1/20 0.37
PARP14 Q460N5 2/20 0.36
TNKS O95271 1/20 0.36
MAP4K1 Q92918 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17899131 0.88 KDM1A (0.51) PARP1EGFRLCKJAK3KDM1A
SCHEMBL17931461 0.84 ALDH1A1 (0.45) KDM1AMAOAKDM1BRCOR1SYK
SCHEMBL21697446 0.83 KCNH2 (0.39) PARP1EGFRLCKJAK3BTK
SCHEMBL21697490 0.83 SIRT2 (0.45)
SCHEMBL16304063 0.79 KCNH2 (0.54) PARP1ESRRGKCNH2ESRRBESR1
SCHEMBL5686231 0.76 SYK (0.50) PARP1EGFRLCKJAK3BTK
SCHEMBL25453173 0.75 HRH3 (0.55) PARP1ESRRGKCNH2ESRRBESR1
SCHEMBL17888665 0.74 AKR1C3 (0.46) KDM1A
SCHEMBL28833626 0.72 JAK3 (0.57) PARP1EGFRLCKJAK3BTK
SCHEMBL1306328 0.70 KCNH2 (0.58) PARP1ESRRGKCNH2ESRRBESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11013728-B2 Cyclin-dependent kinase 8 and/or 19 inhibitor KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2021-05-25 US disclosed
US-20210100783-A1 NOVEL CYCLIN-DEPENDENT KINASE 8 AND/OR 19 INHIBITOR KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2021-04-08 US disclosed
EP-3607944-A1 NOVEL CYCLIN-DEPENDENT KINASE 8 AND/OR 19 INHIBITOR Kyoto Pharmaceutical Industries, Ltd. (JP) 2020-02-12 EP disclosed
US-20160207883-A1 NOVEL AROMATIC COMPOUND AND USE THEREOF KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2016-07-21 US disclosed
US-20160207883-A1 NOVEL AROMATIC COMPOUND AND USE THEREOF KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2016-07-21 US disclosed
EP-3040329-A1 NOVEL AROMATIC COMPOUND AND USE THEREOF Kyoto Pharmaceutical Industries, Ltd. (JP) 2016-07-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160207883-A1 NOVEL AROMATIC COMPOUND AND USE THEREOF SOST, BMP2, ALPI PARP1 4779/4885EGFR 1007/4885LCK 1698/4885
US-20210100783-A1 NOVEL CYCLIN-DEPENDENT KINASE 8 AND/OR 19 INHIBITOR CCNI, CDK9, CDK8 PARP1 1239/4885EGFR 1047/4885LCK 802/4885
US-11013728-B2 Cyclin-dependent kinase 8 and/or 19 inhibitor CCNI, CDK9, CDKN1A PARP1 1274/4885EGFR 1136/4885LCK 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.